Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives

Cancer Discovery

Volumn 3, Issue 3, 2013, Pages 264-279

  Arnedos, Monica ^a,c   Andre, Fabrice ^a,c,d   Soria, Jean Charles ^b,c,e   Dieci, Maria Vittoria ^a,c,e  

^a Breast Cancer Unit   (France)

^b Early Drug Development Unit (SITEP)   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 4547; BEVACIZUMAB; BGJ 398; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRIVANIB; BRIVANIB ALANINATE; CARBOPLATIN; CETUXIMAB; DIURETIC AGENT; DOVITINIB; ENMD 2076; EXEMESTANE; FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR; FULVESTRANT; IMATINIB; LENVATINIB; LY 287445; LY 2874455; MGFR 1877S; NINTEDANIB; ORANTINIB; PACLITAXEL; PHOSPHATE BINDING AGENT; PLACEBO; PONATINIB; PROTEIN INHIBITOR; RABEPRAZOLE; REGORAFENIB; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VEMURAFENIB;

ANGIOGENESIS; BLADDER CANCER; BREAST CANCER; CALCIFICATION; CANCER GROWTH; CANCER THERAPY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; EMBRYO DEVELOPMENT; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; GENE TRANSLOCATION; GLIOBLASTOMA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MICROANGIOPATHY; NAUSEA; NEOPLASM; NONHUMAN; OVARY CANCER; PARACRINE SIGNALING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN HOMEOSTASIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; UBIQUITINATION; UPPER ABDOMINAL PAIN; UTERINE CERVIX CARCINOMA; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84876048479     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0362     Document Type: Review

References (94)

1. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8: 235-53.
2. Holzmann K, Grunt T, Heinzle C, McKeehan WL. Alternative splicing of fi broblast growth factor receptor Ig III loops in cancer. J Nucleic Acids 2012; 2012: 950508.
3. Trueb B. Biology of FGFRL1, the fi fth fi broblast growth factor receptor. Cell Mol Life Sci 2011; 68: 951-64.
4. Turner N, Grose R. Fibroblast growth factor signaling: from development to cancer. Nat Rev Cancer 2010; 10: 116-29.
5. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-97.
6. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fi broblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011; 17: 6130-9.
7. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fi broblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 189: 824-31.
8. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-8.
9. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplifi cation associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
10. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, et al. Mapping of DNA amplifi cations at 15 chromosomal localizations in 1875 breast tumors: defi nition of phenotypic groups. Cancer Res 1997; 57: 4360-7.
11. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DY, et al. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifi cations. Clin Cancer Res 2007; 13: 4731-9.
12. Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 2001; 61: 4514-9.
13. Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Mühling J, Hofele C, et al. Recurrent FGFR1 amplifi cation and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol 2007; 43: 60-6.
14. Ishizuka T, Tanabe C, Sakamoto H, Aoyagi K, Maekawa M, Matsukura N, et al. Gene amplifi cation profi ling of esophageal squamous cell carcinomas by DNA array CGH. Biochem Biophys Res Commun 2002; 296: 152-5.
15. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifi cations associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003; 9: 5271-81.
16. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008; 68: 664-73.
17. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A 2005; 102: 14344-9.
18. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010; 41: 461-76
19. Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004; 5: 287-98.
20. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, et al. FGFR2-amplifi ed gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68: 2340-8.
21. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profi ling of triple negative breast cancers identifi es amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-23.
22. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008; 105: 8713-7.
23. Jang JH, Shin KH, Park JG. Mutations in fi broblast growth factor receptor 2 and fi broblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001; 61: 3541-3.
24. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifi es alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 870-4.
25. Nord H, Segersten U, Sandgren J, Wester K, Busch C, Menzel U, et al. Focal amplifi cations are associated with high-grade and recurrences in stage Ta bladder carcinoma. Int J Cancer 2010; 126: 1390-402.
26. Vékony H, Ylstra B, Wilting SM, Meijer GA, van de Wiel MA, Leemans CR, et al. DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. Clin Cancer Res 2007; 13: 3133-9.
27. van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, et al. Novel fi broblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identifi ed in non-lethal skeletal disorders. Eur J Hum Genet 2002; 10: 819-24.
28. Rosty C, Aubriot MH, Cappellen D, Bourdin J, Cartier I, Thiery JP, et al. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer 2005; 4: 15.
29. Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J, et al. Mutation, SNP, and isoform analysis of fi broblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood 2003; 102: 772-3.
30. Hernández S, de Muga S, Agell L, Juanpere N, Esgueva R, Lorente JA, et al. FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod Pathol 2009; 22: 848-56.
31. Goriely A, Hansen RM, Taylor IB, Olesen IA, Jacobsen GK, McGowan SJ, et al. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet 2009; 41: 1247-52.
32. Zhang Y, Hiraishi Y, Wang H, Sumi KS, Hayashido Y, Toratani S, et al. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer 2005; 117: 166-8.
33. Chesi M, Nardini E, Brents LA, Schröck E, Ried T, Kuehl WM, et al. Frequent translocation t(4;14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fi broblast growth factor receptor 3. Nat Genet 1997; 16: 260-4.
34. Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H, et al. Fusion of ETV6 to fi broblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res 2001; 61: 8371-4.
35. Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, et al. Identifi cation of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009; 119: 3395-407.
36. Frullanti E, Berking C, Harbeck N, Jézéquel P, Haugen A, Mawrin C, et al. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev 2011; 20: 340-7.
37. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007; 110: 3729-34.
38. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441-51.
39. Elbauomy ES, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, et al. FGFR1 amplifi cation in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9: R23.
40. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplifi cation drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res es 2010; 70: 2085-94.
41. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006; 12: 6652-62.
42. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identifi cation of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-67.
43. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA, et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011; 104: 75-82.
44. Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Amorós A, Tardón A, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006; 24: 3664-71.
45. Qing J, Du X, Chen Y, Chan P, Li H, Wu P, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009; 119: 1216-29.
46. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199-213.
47. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to mesenchymal transition. Cancer Cell 2007; 12: 559-71.
48. Feng S, Shao LJ, Yu W, Gavine PR, Ittmann MM. Targeting fi broblast growth factor receptor signaling inhibits prostate cancer progression. Clin Cancer Res 2012; 18: 3880-8.
49. Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 2009; 75: 196-207.
50. Semrad TJ, Mack PC. Fibroblast growth factor signaling in nonsmall-cell lung cancer. Clin Lung Cancer 2012; 13: 90-5.
51. Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011; 17: 5275-86.
52. Compagni A, Wilgenbus P, Impagnatiello M-A, Cotten M, Christofori G. Fibroblast growth factors are required for effi cient tumor angiogenesis. Cancer Res 2000; 60: 7163-9.
53. Wang Y, Becker D. Antisense targeting of basic fi broblast growth factor and fi broblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3: 887-93.
54. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identifi ed fi broblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 2007; 25: 2281-7.
55. Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R, et al. Distinct role of fi broblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 2003; 162: 1913-26.
56. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
57. Allen E, Walters I, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both fi rst and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 2011; 17: 5299-310.
58. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-9.
59. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487: 500-4.
60. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008; 5: e19.
61. Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE 2010; 5: e14117.
62. Oliveras-Ferraros C, Cufí S, Queralt B, Vazquez-Martin A, Martin-Castillo B, de Llorens R, et al. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br J Cancer 2012; 106: 1406-14.
63. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 2012; 287: 28087-98.
64. Lee SH, Lopes de MD, Vora J, Harris A, Ye H, Nordahl L, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005; 11: 3633-41.
65. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor effi cacy. Cancer Res 2008; 68: 4774-82.
66. Bello E, Colella G, Scarlato V, Oliva P, Berndt A, Valbusa G, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 2011; 71: 1396-405.
67. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008; 122: 664-71.
68. Bhide R, Cai Z-W, Zhang Y-Z, Qian L, Wei D, Barbosa S, et al. Discovery and preclinical studies of (R)-1-(4-(4-fl uoro-2-methyl-1Hindol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006; 49: 2143-6.
69. Fletcher GC, Brokx RD, Denny TA, Hembrough TA, Plum SM, Fogler WE, et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther 2011; 10: 126-37.
70. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60: 4152-60.
71. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-12.
72. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fi broblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72: 2045-56.
73. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fi broblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54: 7066-83.
74. Zhao G, Li WY, Chen D, Henry JR, Li HY, Chen Z, et al. A novel, selective inhibitor of fi broblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther 2011; 10: 2200-10.
75. Long L, Brennan T, Zanghi J, Palencia S, Cheung R, Aguirre M, et al. Antitumor effi cacy of FP-1039, a soluble FGF receptor 1:Fc conjugate, as a single agent or in combination with anticancer drugs [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 17-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2789.
76. Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 2075-81.
77. Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fi broblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 2011; 17: 7451-61.
78. Soria JC, Dienstmann R, de Braud F, Cereda R, Bahleda R, Hollebecque A, et al. First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. Ann Oncol 2012;23(Suppl 1):i15-i25, abstr L2.5.
79. Mross K, Stefanic M, Gmehling D, Frost A, Baas F, Unger C, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 311-9.
80. Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010; 9: 2825-33.
81. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplifi ed or mutated cancer models. Mol Cancer Ther 2012; 11: 690-9.
82. Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol 2011; 22: 1413-9.
83. Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Cancer Res 2011; 17: 2528-37.
84. Wolf J, LoRusso PM, Camidge RD, Perez JM, Tabernero J, Hidalgo M, et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors [abstract]. In: Proceedings of the103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; 2012. Abstract nr LB-122.
85. Andre F, Bachelot D, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, et al. A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplifi ed and non-amplifi ed metastatic breast cancer. J Clin Oncol 2011; 29 (suppl; abstr 508).
86. Angevin E, Grunwald V, Ravaud A, Castellano DE, Lin CC, Gschwend JE, et al. A phase II study of dovitinib (TKI258), an FGFR-and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol 2011; 29 (suppl; abstr 4551).
87. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-45.
88. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; 29: 3798-804.
89. George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012; 30: 2401-7.
90. Sun HD, Malabunga M, Tonra JR, DiRenzo R, Carrick FE, Zheng H, et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrinol Metab 2007; 292: E964-76.
91. Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol 2011; 29: 1236-8.
92. Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, et al. Co-amplifi ed genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 2009; 28: 1892-903.
93. Koziczak M, Hynes NE. Cooperation between fi broblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem 2004; 279: 50004-11.
94. Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A. Resistance to chemotherapy is associated with fi broblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009; 15: 2058-66.